October 13, 2003
Novartis Pharma switched to independent marketing for all dosage forms except eye drops of its allergic disease treatment Zaditen (ketotifen) on October 1. The company had comarketed Zaditen with Torii Pharmaceutical since January 2001. The two companies initially planned to...read more